NCT05642429 - Study of AV-1959D, an Amyloid Beta Vaccine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 27, 2023

Primary Completion Date

February 20, 2026

Study Completion Date

November 7, 2026

Conditions

Alzheimer Disease

Interventions

BIOLOGICAL

AV-1959D

Three doses of AV-1959D administered as a sterile suspension via intradermal injection

BIOLOGICAL

Placebo

Three doses of Placebo administered as a sterile suspension via intradermal injection

Trial Locations (6)

Accel Research, Decatur

Alzheimer's Research and Treatment Center, Wellington

University of South Florida, Tampa

Banner Alzheimer's Institute, Phoenix

Hoag Memorial Hospital, Newport Beach

Global Medical Institutes Princeton Medical Institute, Princeton